The data shown below were collected from the profiles of 43 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
| Title |
Pharmacotherapeutic considerations for use of cannabinoids to relieve pain in patients with malignant diseases
|
|---|---|
| Published in |
Journal of Pain Research, April 2018
|
| DOI | 10.2147/jpr.s160556 |
| Pubmed ID | |
| Authors |
Marija Darkovska-Serafimovska, Tijana Serafimovska, Zorica Arsova-Sarafinovska, Sasho Stefanoski, Zlatko Keskovski, Trajan Balkanov |
| Abstract |
The aim of this review was to assess the efficacy of cannabis preparations for relieving pain in patients with malignant diseases, through a systematic review of randomized controlled trials (RCTs), which were predominantly double-blind trials that compared cannabis preparation to a placebo. An electronic search of all literature published until June 2017 was made in MEDLINE/PubMed, Embase, The Cochrane Controlled Trials Register and specific web pages devoted to cannabis. Fifteen of the 18 trials demonstrated a significant analgesic effect of cannabinoids as compared to placebo. The most commonly reported adverse effects were generally well tolerated, mild to moderate. The main side effects were drowsiness, nausea, vomiting and dry mouth. There is evidence that cannabinoids are safe and modestly effective in neuropathic pain and also for relieving pain in patients with malignant diseases. The proportion of "responders" (patients who at the end of 2 weeks of treatment reported ≥30% reduction in pain intensity on a scale of 0-10, which is considered to be clinically important) was 43% in comparison with placebo (21%). The target dose for relieving pain in patients with malignant diseases is most likely about 10 actuations per day, which is about 27 mg tetrahydrocannabinol (THC) and 25 mg cannabidiol (CBD), and the highest approved recommended dose is 12 actuations per day (32 mg THC/30 mg CBD). Further large studies of cannabinoids in homogeneous populations are required. |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 13 | 30% |
| Canada | 3 | 7% |
| Sierra Leone | 2 | 5% |
| Chile | 2 | 5% |
| Spain | 1 | 2% |
| Netherlands | 1 | 2% |
| Germany | 1 | 2% |
| United Kingdom | 1 | 2% |
| Unknown | 19 | 44% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 40 | 93% |
| Practitioners (doctors, other healthcare professionals) | 1 | 2% |
| Science communicators (journalists, bloggers, editors) | 1 | 2% |
| Scientists | 1 | 2% |
Mendeley readers
The data shown below were compiled from readership statistics for 169 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 169 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 23 | 14% |
| Student > Bachelor | 21 | 12% |
| Student > Master | 14 | 8% |
| Other | 12 | 7% |
| Student > Doctoral Student | 10 | 6% |
| Other | 26 | 15% |
| Unknown | 63 | 37% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 33 | 20% |
| Pharmacology, Toxicology and Pharmaceutical Science | 17 | 10% |
| Nursing and Health Professions | 12 | 7% |
| Biochemistry, Genetics and Molecular Biology | 9 | 5% |
| Neuroscience | 6 | 4% |
| Other | 30 | 18% |
| Unknown | 62 | 37% |
Attention Score in Context
This research output has an Altmetric Attention Score of 503. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 May 2024.
All research outputs
#53,593
of 26,175,232 outputs
Outputs from Journal of Pain Research
#6
of 2,031 outputs
Outputs of similar age
#1,223
of 347,489 outputs
Outputs of similar age from Journal of Pain Research
#1
of 47 outputs
Altmetric has tracked 26,175,232 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,031 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 14.5. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 347,489 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 47 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 97% of its contemporaries.